Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
FiscalNote reported Q3 2026 revenue of $18.7 million and a significantly narrowed net loss of $5.9 million compared to $24.9 million in the prior year. The company achieved an Adjusted EBITDA of $3.6 million, driven by cost efficiencies and the divestiture of its FrontierView business to sharpen focus on core AI-driven policy intelligence.
Term
Q3 2026
“Our focus this quarter was on maturing product delivery while continuing to realize the cost efficiencies now showing up in our profitability. Our go-forward priority is on the assets our customers can’t get anywhere else: our decades of policy journalism and our deep bank of proprietary legislative and regulatory data, delivered through PolicyNote and our PolicyNote APIs and MCP integrations which embed our intelligence directly into our customers’ agentic workflows.”
Natalia Mirgorodskaya informed Upstart Holdings of her intent to resign as Chief Accounting Officer, effective November 30, 2026, to pursue another opportunity. CFO Andrea Blankmeyer will serve as Interim Principal Accounting Officer while the company searches for a permanent replacement.
Jing An, CFO, sold 13,000 shares of Luckin Coffee Inc. at $33.78 a share, worth $439K in total on Nov 5, 2026. Shares held after the trade: 215,784 (-5.7%).
Delta Air Lines EVP & Pres. - International Alain Bellemare Sells $2.41M of Stock
Alain Bellemare, EVP & Pres. - International, sold 28,000 shares of Delta Air Lines, Inc. at $85.82 to $86.06 a share (average $85.93) in 2 transactions, worth $2.41M in total on Nov 6, 2026. Shares held after the trade: 80,025 (-14.0%).
Mercury General Director Joshua Eric Little Buys $62K of Stock
Joshua Eric Little, Director, bought 750 shares of Mercury General Corp at $82.69 a share, worth $62K in total on Nov 6, 2026. Shares held after the trade: 4,000 (+23.1%).
Flowco Holdings President and CEO Joseph R. Edwards Buys $798K of Stock
Joseph R. Edwards, President and CEO, bought 41,000 shares of Flowco Holdings Inc. at $19.46 to $19.49 a share (average $19.47) in 2 transactions, worth $798K in total on Nov 5, 2026. Shares held after the trade: 25,500.
Flowco Holdings Director Alexander Chmelev Buys $13.2K of Stock
Alexander Chmelev, Director, bought 700 shares of Flowco Holdings Inc. at $18.86 a share, worth $13.2K in total on Nov 5, 2026. Shares held after the trade: 24,625 (+2.9%).
Stryker Insider Ronda E. Stryker Sells $179M of Stock
Ronda E. Stryker sold 550,000 shares of Stryker Corp at $323.19 to $327.69 a share (average $325.32) in 6 transactions, worth $179M in total on Nov 6, 2026. Shares held after the trade: 1,701,375 (-0.6%).
Fahmi Karam, CEO, bought 12,165 shares of Upbound Group, Inc. at $24.66 a share, worth $300K in total on Nov 5, 2026. Shares held after the trade: 271,077 (+4.7%).
American Financial Group SVP, CFO Brian S. Hertzman Sells $46.7K of Stock
Brian S. Hertzman, SVP, CFO, sold 301 shares of American Financial Group Inc at $155.29 a share, worth $46.7K in total on Nov 6, 2026. Shares held after the trade: 1,553 (-16.2%).
Babcock & Wilcox Enterprises reported a significant increase in revenues for the nine months ended September 30, 2026, reaching $824.9 million compared to $426.7 million in the prior year period. The company successfully redeemed its 6.50% and 8.125% Senior Notes during 2026 and 2025, respectively, while issuing new 8.75% Senior Secured Notes due 2030.
PubMatic reported revenue of $79.6 million for the third quarter of 2026, a 17% increase year-over-year, and returned to profitability with a net income of $5.5 million. Despite the quarterly gain, the company recorded a net loss of $8.2 million for the first nine months of 2026, though this was a significant improvement from the $21.1 million loss in the prior year period.
Trex Co President and CEO Adam Dante Zambanini Sells $27.9K of Stock
Adam Dante Zambanini, President and CEO, sold 500 shares of Trex Co Inc at $55.84 a share, worth $27.9K in total on Nov 9, 2026. Shares held after the trade: 235,505 (-0.2%).
Ocular Therapeutix Chief Business Officer Namrata Saroj Sells $232K of Stock
Namrata Saroj, Chief Business Officer, sold 35,370 shares of Ocular Therapeutix, Inc at $6.55 a share, worth $232K in total on Nov 5, 2026. Shares held after the trade: 220,522 (-13.8%).
Edwards Lifesciences CVP,Strategy/Corp Development Donald E. Bobo Jr. Sells $5.04M of Stock
Donald E. Bobo Jr., CVP,Strategy/Corp Development, sold 48,900 shares of Edwards Lifesciences Corp at $103.05 a share, worth $5.04M in total on Nov 9, 2026. Shares held after the trade: 22,798 (-68.2%).
Ed Hallen sold 98,782 shares of Klaviyo, Inc. at $20.71 to $21.52 a share (average $21.35) in 4 transactions, worth $2.11M in total on Nov 5, 2026. Shares held after the trade: 310,631 (-4.3%).
Edwards Lifesciences CEO Bernard J. Zovighian Sells $2.38M of Stock
Bernard J. Zovighian, CEO, sold 23,100 shares of Edwards Lifesciences Corp at $102.78 to $103.39 a share (average $103.02) in 2 transactions, worth $2.38M in total on Nov 9, 2026. Shares held after the trade: 98,845 (-12.3%).
Kochav Defense Acquisition Corp. announced an update to its trust account contribution terms ahead of an extraordinary general meeting to extend its business combination deadline. The sponsor will now contribute a flat $300,000 for the first three months and $100,000 per month thereafter, replacing a previous per-share calculation. Additionally, the company will reduce the permitted withdrawal of interest from the trust account for dissolution expenses from $100,000 to zero.
Klaviyo Insider Roxanne Oulman Sells $285K of Stock
Roxanne Oulman sold 13,989 shares of Klaviyo, Inc. at $20.36 a share, worth $285K in total on Nov 6, 2026. Shares held after the trade: 23,354 (-37.5%).
Surrozen is transitioning to a clinical-stage company with a dual-mechanism approach for retinal diseases, backed by a $95 million financing tranche triggered by IND opening.
Trevi Therapeutics reported a net loss of $52.4 million for the nine months ended September 30, 2026, compared to $34.4 million in the prior year, primarily driven by increased R&D expenses for its Haduvio clinical trials. The company significantly strengthened its balance sheet through a common stock offering, ending the period with $299.4 million in cash, cash equivalents, and marketable securities.
Green Dot Corporation reported Q3 2026 financial results with total operating revenues of $601.1 million, a 21% increase year-over-year. The company reported a GAAP net loss of $7.4 million, showing significant improvement from the $30.8 million loss in the prior year period. Management highlighted growth in the embedded finance space as the company prepares for its pending acquisition by Smith Ventures and CommerceOne.
“Green Dot delivered another strong quarter of growth and efficiency, which were bolstered by our continued efforts to improve operations, optimize our balance sheet and capitalize on increasing demand and opportunity in the embedded finance space.”
William I Jacobs, Chairman and Chief Executive Officer
“I am proud of the team’s continued focus and commitment to our customers and partners, particularly as we prepare for our next chapter with Smith Ventures and CommerceOne.”
William I Jacobs, Chairman and Chief Executive Officer
Emerson Electric Co. reported fiscal 2026 net sales of $19.0 billion, a 5% increase over the prior year, with net earnings from continuing operations rising 19% to $2.69 billion. The company transitioned to mark-to-market accounting for pension plans and reported adjusted diluted EPS of $6.59, reflecting strong operating performance and sales growth.
Infinity Natural Resources reported a significant increase in total revenues to $523.5 million for the nine months ended September 30, 2026, compared to $239.4 million in the prior year, driven by higher oil and gas sales. The company swung to a net income of $101.3 million for the period, up from a net loss of $16.4 million in 2025, despite a $72.0 million loss on derivative instruments. Significant activity included the $620.5 million Antero Acquisition and the issuance of $350 million in Series A Preferred Stock.
Trevi Therapeutics reported financial results for the third quarter of 2026, highlighting the initiation of its Phase 3 OCEAN-2 trial for IPF-related chronic cough. The company also reached alignment with the FDA on a Phase 2 development path for non-IPF ILD-related chronic cough, with a trial expected to start in Q1 2027. Trevi maintains a cash runway into 2030 to fund its key clinical milestones.
Term
Q3 2026
“This is an important time of clinical execution for Trevi as we actively open sites globally and enroll patients across all three active trials. We also recently aligned with the FDA on our non-IPF ILD-related chronic cough program and expect to initiate a Phase 2 dose-ranging trial in the first quarter of 2027.”
Jennifer Good, President and CEO of Trevi Therapeutics
Babcock & Wilcox reported Q3 2026 revenue of $291 million, a 109% year-over-year increase, driven by strong demand from utilities and data centers. The company reported net income of $94 million and reiterated its full-year 2026 Adjusted EBITDA guidance of $80 million to $105 million. Management highlighted a $16 billion global pipeline, including 6 gigawatts of opportunities in the data center market.
Term
Q3 2026
“B&W maintained its strong performance in the third quarter of 2026, reflecting continued demand across all of our businesses and sustained operational momentum. Rising global electricity demand is fueling increased needs from utilities, industrial and data center customers for our parts and services businesses and continues to drive new power generation opportunities.”
Kenneth Young, B&W's Chairman and Chief Executive Officer
“Our strong financial performance was underpinned by significant development in our bookings and backlog pipeline, setting the stage for continued growth in future quarters. During the third quarter, revenue and Adjusted EBITDA exceeded consensus street expectations and we continue to see positive momentum across our business.”
Kenneth Young, B&W's Chairman and Chief Executive Officer
Octave Specialty Group reported total assets of $2.30 billion as of September 30, 2026, with a notable increase in commissions revenue to $165.9 million for the first nine months of 2026 compared to $103.2 million in 2025. The company maintains a significant specialty property and casualty insurance presence, though it faces risks related to underwriting losses and stock price volatility.
Key Tronic reported a net loss of $7.5 million for the quarter ended September 26, 2026, compared to a $2.3 million loss in the prior year, driven by a significant decline in gross profit. Despite flat net sales of approximately $98.7 million, the company faced increased costs of sales and operating expenses, partially offset by a $3.2 million net gain from insurance proceeds.
Franklin Templeton reported a significant increase in fiscal year 2026 performance, with operating income rising 95% to $1.18 billion and total AUM growing 8% to $1.80 trillion. Growth was driven by $84.1 billion in long-term net inflows and $126.1 billion in market appreciation, despite $11.7 billion in net outflows at Western Asset Management.
Gladstone Investment Corporation reported financial results for its second fiscal quarter ended September 30, 2026, with total investment income of $24.2 million. The company reported net investment income of $4.8 million ($0.12 per share) and a net asset value per common share of $16.43. During the quarter, the company invested $156.5 million and maintained a portfolio of 31 companies.